Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan registered : validation in chronic hepatitis C
A novel controlled attenuation parameter (CAP) has been developed for Fibroscan registered to assess liver steatosis, simultaneously with liver stiffness measurement (LSM). We assessed CAP diagnostic accuracy in a large cohort of patients with chronic hepatitis C (CHC) virus. A total of 615 patients...
Gespeichert in:
| Veröffentlicht in: | Journal of viral hepatitis 2012-04, Vol.19 (4), p.244-253 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 253 |
|---|---|
| container_issue | 4 |
| container_start_page | 244 |
| container_title | Journal of viral hepatitis |
| container_volume | 19 |
| creator | Sasso, M Tengher-Barna, I Ziol, M Miette, V Fournier, C Sandrin, L Poupon, R Cardoso, A-C Marcellin, P Douvin, C de Ledinghen, V Trinchet, J-C Beaugrand, M |
| description | A novel controlled attenuation parameter (CAP) has been developed for Fibroscan registered to assess liver steatosis, simultaneously with liver stiffness measurement (LSM). We assessed CAP diagnostic accuracy in a large cohort of patients with chronic hepatitis C (CHC) virus. A total of 615 patients with CHC, who underwent both Fibroscan registered and liver biopsy, were analysed. Fibrosis was graded using METAVIR score. Steatosis was categorized by visual assessment as S0: steatosis in |
| doi_str_mv | 10.1111/j.1365-2893.2011.01534.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_968178480</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>968178480</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_9681784803</originalsourceid><addsrcrecordid>eNqNjMtOw0AMRUcIJMrjH7xjlTCTR0nZVlSsWLGvTOq0U03sMp5E_AT_zCAQa-7GVz72MQacLV3O_bF09bItqm5Vl5V1rrSurZvy48ws_sD5d2-rwra2uTRXqkdrXV21bmE-X2SmAL1wihIC7QBTIp4weWE4YcSREkUYJAILe55R_UyAqqQ6EieQATQRJlGvMKnnPWz8WxTtkSHS3mcas_gRZgx-92P2DP0hZmEPBzrlXcrP6xtzMWBQuv2d1-Zu8_S6fi5OUd4n0rQdvfYUAjLJpNvVsnMPXdPZ-v-XXy5PYwM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>968178480</pqid></control><display><type>article</type><title>Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan registered : validation in chronic hepatitis C</title><source>Wiley Online Library All Journals</source><creator>Sasso, M ; Tengher-Barna, I ; Ziol, M ; Miette, V ; Fournier, C ; Sandrin, L ; Poupon, R ; Cardoso, A-C ; Marcellin, P ; Douvin, C ; de Ledinghen, V ; Trinchet, J-C ; Beaugrand, M</creator><creatorcontrib>Sasso, M ; Tengher-Barna, I ; Ziol, M ; Miette, V ; Fournier, C ; Sandrin, L ; Poupon, R ; Cardoso, A-C ; Marcellin, P ; Douvin, C ; de Ledinghen, V ; Trinchet, J-C ; Beaugrand, M</creatorcontrib><description>A novel controlled attenuation parameter (CAP) has been developed for Fibroscan registered to assess liver steatosis, simultaneously with liver stiffness measurement (LSM). We assessed CAP diagnostic accuracy in a large cohort of patients with chronic hepatitis C (CHC) virus. A total of 615 patients with CHC, who underwent both Fibroscan registered and liver biopsy, were analysed. Fibrosis was graded using METAVIR score. Steatosis was categorized by visual assessment as S0: steatosis in <10% of hepatocytes, S1: 11-33%, S2: 34-66% and S3: 67-100%. Performances of CAP and liver stiffness were determined using receiver operating characteristic (ROC) curve analysis and cross-validated using the bootstrap method. The Obuchowski measure was used to assess overall accuracy of CAP and to differentiate between steatosis grades. In multivariate analysis, CAP was related to steatosis (P<10-15) independently of fibrosis stage (which was related to LSM). The areas under ROC curves using CAP to detect steatosis were 0.80 (95% CI, 0.75-0.84) for S greater than or equal to S1, 0.86 (0.81-0.92) for S greater than or equal to S2 and 0.88 (0.73-1) S=S3. CAP exhibited a good ability to differentiate steatosis grades (Obuchowski measure=0.92). Performance of LSM for fibrosis assessment confirmed results from previous studies. CAP is a novel tool to assess the degree of steatosis and both fibrosis and steatosis can be evaluated noninvasively during the same procedure using Fibroscan registered , in patients with CHC.</description><identifier>ISSN: 1352-0504</identifier><identifier>EISSN: 1365-2893</identifier><identifier>DOI: 10.1111/j.1365-2893.2011.01534.x</identifier><language>eng</language><ispartof>Journal of viral hepatitis, 2012-04, Vol.19 (4), p.244-253</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Sasso, M</creatorcontrib><creatorcontrib>Tengher-Barna, I</creatorcontrib><creatorcontrib>Ziol, M</creatorcontrib><creatorcontrib>Miette, V</creatorcontrib><creatorcontrib>Fournier, C</creatorcontrib><creatorcontrib>Sandrin, L</creatorcontrib><creatorcontrib>Poupon, R</creatorcontrib><creatorcontrib>Cardoso, A-C</creatorcontrib><creatorcontrib>Marcellin, P</creatorcontrib><creatorcontrib>Douvin, C</creatorcontrib><creatorcontrib>de Ledinghen, V</creatorcontrib><creatorcontrib>Trinchet, J-C</creatorcontrib><creatorcontrib>Beaugrand, M</creatorcontrib><title>Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan registered : validation in chronic hepatitis C</title><title>Journal of viral hepatitis</title><description>A novel controlled attenuation parameter (CAP) has been developed for Fibroscan registered to assess liver steatosis, simultaneously with liver stiffness measurement (LSM). We assessed CAP diagnostic accuracy in a large cohort of patients with chronic hepatitis C (CHC) virus. A total of 615 patients with CHC, who underwent both Fibroscan registered and liver biopsy, were analysed. Fibrosis was graded using METAVIR score. Steatosis was categorized by visual assessment as S0: steatosis in <10% of hepatocytes, S1: 11-33%, S2: 34-66% and S3: 67-100%. Performances of CAP and liver stiffness were determined using receiver operating characteristic (ROC) curve analysis and cross-validated using the bootstrap method. The Obuchowski measure was used to assess overall accuracy of CAP and to differentiate between steatosis grades. In multivariate analysis, CAP was related to steatosis (P<10-15) independently of fibrosis stage (which was related to LSM). The areas under ROC curves using CAP to detect steatosis were 0.80 (95% CI, 0.75-0.84) for S greater than or equal to S1, 0.86 (0.81-0.92) for S greater than or equal to S2 and 0.88 (0.73-1) S=S3. CAP exhibited a good ability to differentiate steatosis grades (Obuchowski measure=0.92). Performance of LSM for fibrosis assessment confirmed results from previous studies. CAP is a novel tool to assess the degree of steatosis and both fibrosis and steatosis can be evaluated noninvasively during the same procedure using Fibroscan registered , in patients with CHC.</description><issn>1352-0504</issn><issn>1365-2893</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqNjMtOw0AMRUcIJMrjH7xjlTCTR0nZVlSsWLGvTOq0U03sMp5E_AT_zCAQa-7GVz72MQacLV3O_bF09bItqm5Vl5V1rrSurZvy48ws_sD5d2-rwra2uTRXqkdrXV21bmE-X2SmAL1wihIC7QBTIp4weWE4YcSREkUYJAILe55R_UyAqqQ6EieQATQRJlGvMKnnPWz8WxTtkSHS3mcas_gRZgx-92P2DP0hZmEPBzrlXcrP6xtzMWBQuv2d1-Zu8_S6fi5OUd4n0rQdvfYUAjLJpNvVsnMPXdPZ-v-XXy5PYwM</recordid><startdate>20120401</startdate><enddate>20120401</enddate><creator>Sasso, M</creator><creator>Tengher-Barna, I</creator><creator>Ziol, M</creator><creator>Miette, V</creator><creator>Fournier, C</creator><creator>Sandrin, L</creator><creator>Poupon, R</creator><creator>Cardoso, A-C</creator><creator>Marcellin, P</creator><creator>Douvin, C</creator><creator>de Ledinghen, V</creator><creator>Trinchet, J-C</creator><creator>Beaugrand, M</creator><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>20120401</creationdate><title>Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan registered : validation in chronic hepatitis C</title><author>Sasso, M ; Tengher-Barna, I ; Ziol, M ; Miette, V ; Fournier, C ; Sandrin, L ; Poupon, R ; Cardoso, A-C ; Marcellin, P ; Douvin, C ; de Ledinghen, V ; Trinchet, J-C ; Beaugrand, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_9681784803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sasso, M</creatorcontrib><creatorcontrib>Tengher-Barna, I</creatorcontrib><creatorcontrib>Ziol, M</creatorcontrib><creatorcontrib>Miette, V</creatorcontrib><creatorcontrib>Fournier, C</creatorcontrib><creatorcontrib>Sandrin, L</creatorcontrib><creatorcontrib>Poupon, R</creatorcontrib><creatorcontrib>Cardoso, A-C</creatorcontrib><creatorcontrib>Marcellin, P</creatorcontrib><creatorcontrib>Douvin, C</creatorcontrib><creatorcontrib>de Ledinghen, V</creatorcontrib><creatorcontrib>Trinchet, J-C</creatorcontrib><creatorcontrib>Beaugrand, M</creatorcontrib><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of viral hepatitis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sasso, M</au><au>Tengher-Barna, I</au><au>Ziol, M</au><au>Miette, V</au><au>Fournier, C</au><au>Sandrin, L</au><au>Poupon, R</au><au>Cardoso, A-C</au><au>Marcellin, P</au><au>Douvin, C</au><au>de Ledinghen, V</au><au>Trinchet, J-C</au><au>Beaugrand, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan registered : validation in chronic hepatitis C</atitle><jtitle>Journal of viral hepatitis</jtitle><date>2012-04-01</date><risdate>2012</risdate><volume>19</volume><issue>4</issue><spage>244</spage><epage>253</epage><pages>244-253</pages><issn>1352-0504</issn><eissn>1365-2893</eissn><abstract>A novel controlled attenuation parameter (CAP) has been developed for Fibroscan registered to assess liver steatosis, simultaneously with liver stiffness measurement (LSM). We assessed CAP diagnostic accuracy in a large cohort of patients with chronic hepatitis C (CHC) virus. A total of 615 patients with CHC, who underwent both Fibroscan registered and liver biopsy, were analysed. Fibrosis was graded using METAVIR score. Steatosis was categorized by visual assessment as S0: steatosis in <10% of hepatocytes, S1: 11-33%, S2: 34-66% and S3: 67-100%. Performances of CAP and liver stiffness were determined using receiver operating characteristic (ROC) curve analysis and cross-validated using the bootstrap method. The Obuchowski measure was used to assess overall accuracy of CAP and to differentiate between steatosis grades. In multivariate analysis, CAP was related to steatosis (P<10-15) independently of fibrosis stage (which was related to LSM). The areas under ROC curves using CAP to detect steatosis were 0.80 (95% CI, 0.75-0.84) for S greater than or equal to S1, 0.86 (0.81-0.92) for S greater than or equal to S2 and 0.88 (0.73-1) S=S3. CAP exhibited a good ability to differentiate steatosis grades (Obuchowski measure=0.92). Performance of LSM for fibrosis assessment confirmed results from previous studies. CAP is a novel tool to assess the degree of steatosis and both fibrosis and steatosis can be evaluated noninvasively during the same procedure using Fibroscan registered , in patients with CHC.</abstract><doi>10.1111/j.1365-2893.2011.01534.x</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-0504 |
| ispartof | Journal of viral hepatitis, 2012-04, Vol.19 (4), p.244-253 |
| issn | 1352-0504 1365-2893 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_968178480 |
| source | Wiley Online Library All Journals |
| title | Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan registered : validation in chronic hepatitis C |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T21%3A00%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20controlled%20attenuation%20parameter%20for%20noninvasive%20assessment%20of%20steatosis%20using%20Fibroscan%20registered%20:%20validation%20in%20chronic%20hepatitis%20C&rft.jtitle=Journal%20of%20viral%20hepatitis&rft.au=Sasso,%20M&rft.date=2012-04-01&rft.volume=19&rft.issue=4&rft.spage=244&rft.epage=253&rft.pages=244-253&rft.issn=1352-0504&rft.eissn=1365-2893&rft_id=info:doi/10.1111/j.1365-2893.2011.01534.x&rft_dat=%3Cproquest%3E968178480%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=968178480&rft_id=info:pmid/&rfr_iscdi=true |